Procter & Gamble Health working capital

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY25Jun 2024FY24Jun 2023FY23 and earlierAlpha Plus
134.74×126.17×
FY23 and earlierEvery year the company has filed comes with Alpha Plus.
31.87×29.56×
223.07×208.33×
−56.46×−52.60×
3.89×2.50×
1.21×1.23×
1.14×1.03×
0.75×0.73×
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

PGHL₹5,513.50

Procter & Gamble Health Limited

· Pharma & Health
₹ CrorePeersSANOFICONRSANOFISENORESINNOVACAPMOREPENLABIOLCPFDCASTRAZENMcap ₹9,152 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
30/06/2023
FY25
30/06/2024
FY26
30/06/2025
FY27
30/06/2026
Inventory Days (DIO)126.17134.74——
Receivable Days (DSO)29.5631.87——
Payable Days (DPO)208.33223.07——
Cash Conversion Cycle (days)-52.60-56.46——
Working Capital Turnover2.503.89——
Asset Turnover1.231.21——
Cash Conversion (CFO/Net Income)1.031.14——
CFO/EBITDA0.730.75——
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY27 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.